Short Interest Summary: Time to Reconsider Acasti Pharma Class A (NASDAQ:ACST) After Less Short Sellers?

November 23, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Summary: Time to Reconsider Acasti Pharma Class A (NASDAQ:ACST) After Less Short Sellers?

The stock of Acasti Pharma Class A (NASDAQ:ACST) registered a decrease of 94.4% in short interest. ACST’s total short interest was 1,900 shares in November as published by FINRA. Its down 94.4% from 33,900 shares, reported previously. With 10,600 shares average volume, it will take short sellers 0 days to cover their ACST’s short positions. The short interest to Acasti Pharma Class A’s float is 0.04%. About 13,727 shares traded hands. Acasti Pharma Inc (NASDAQ:ACST) has declined 9.66% since April 21, 2016 and is downtrending. It has underperformed by 14.98% the S&P500.

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $14.03 million. The Firm is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. It currently has negative earnings. The Firm is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.

More notable recent Acasti Pharma Inc (NASDAQ:ACST) news were published by: 247Wallst.com which released: “Acasti Pharma Share Gains Massive in Percentage Terms, Tiny in Dollars” on September 14, 2016, also Quotes.Wsj.com with their article: “News Acasti Pharma Inc.ACST” published on January 08, 2013, Streetinsider.com published: “Form 6-K Acasti Pharma Inc. For: Oct 26” on October 26, 2016. More interesting news about Acasti Pharma Inc (NASDAQ:ACST) were released by: Marketwired.com and their article: “Acasti Pharma Reports Second Quarter 2017 Financial Results” published on October 11, 2016 as well as Globenewswire.com‘s news article titled: “Acasti Announces 1-for-10 Reverse Stock Split” with publication date: September 29, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>